Amicus Therapeutics is a renowned research leader in rare as well as orphan ailments. Based in New Jersey, Amicus Therapeutics is a biopharmaceutical firm with a prime focus on the development of technologies utilized in therapy for the treatment of a broad range of illnesses. Primarily, the entity focuses mostly on rare and orphan diseases. Moreover, the emphasis of the Amicus Therapeutics has been given to three core elements as the basis for the development of therapeutic remedies.


Normally, the disease has to be strictly rare, and the technology should have the potential to be of high quality as well as the data available must translate to substantial benefits for the patients. The firm has taken upon itself to cultivate compassionate and personal approaches to patients in addition to their caregivers and the entire family at large. The profound culture has been heavily instrumental in the entity’s focus specifically in the advancement of treatments for CDKL5 deficiency, Epidermolysis Bullosa as well as Lysosomal Storage Disorders.


Amicus Therapeutics has managed to set a patient advocacy forum, Amicus Patient & Professional Advocacy, which partners with numerous stakeholders such as patients, healthcare practitioners, families, and caregivers as well as other concerned parties to deliver top-notch quality support system for individuals living with various rare medical conditions (SeekingAlpha). The firm’s global headquarters are in the United Kingdom’s Buckinghamshire. Moreover, the company has operations in other countries including; France, Italy, Germany, Spain and the Netherlands. The corporate headquarters of Amicus Therapeutics is in Cranbury, New Jersey, USA.


Amicus Therapeutics leverages a team of dedicated professionals, which is led by chair John F. Crowley. John’s experience in therapeutic cure runs back to 1998 when two of his children were sadly diagnosed with a rare and severe neuromuscular disorder, a condition called Pompe Disease. Crowley co-founded the successful Novazyme Pharmaceuticals, which strived to research the Pompe Disease, and was of substantial contribution to saving the lives of his two children. Later, Crowley bought the enterprise and remained as its senior vice president. Thus, Amicus Therapeutics is in the hands of an adeptly qualified, skilled and experienced individual with a significant comprehension of the effects of rare ailments. The company has partnered with numerous organizations over time, and they recently applied a request for authorization to market a drug which is meant to cure Fabry disease, migalastat.

More about Amicus Therapeutics at